z-logo
Premium
Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors
Author(s) -
Yabe Hiroki,
Tsukahara Tomohide,
Kawaguchi Satoshi,
Wada Takuro,
Torigoe Toshihiko,
Sato Noriyuki,
Terai Chihiro,
Aoki Masaya,
Hirose Shigemichi,
Morioka Hideo,
Yabe Hiroo
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21829
Subject(s) - cd8 , human leukocyte antigen , immunohistochemistry , medicine , sarcoma , immune system , monoclonal antibody , immunology , biopsy , hla g , antibody , antigen , cancer research , pathology
Background Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T‐cell infiltration has yet to be reported. Methods Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti‐HLA class I monoclonal antibody (mAb) EMR8‐5 and anti‐CD8 mAb, respectively. Results Expression of HLA class I was negative in 10 tumors and down‐regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down‐regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions Our results suggested that CD8+ T cell‐mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT. J. Surg. Oncol. J. Surg. Oncol. 2011; 103:380–385. © 2010 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom